Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer

Published:2024 Issue:5 Volume:35 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Huo Gengwei¹²³⁴^ORCID,Liu Wenjie¹²³⁴^ORCID,Chen Peng¹²³⁴^ORCID

Affiliation:

1. Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

2. National Clinical Research Center for Cancer, Tianjin, China.

3. Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.

4. Tianjin’s Clinical Research Center for Cancer, Tianjin, China.

Funder

China anti-cancer association HER2 target Chinese research fund

Tianjin education commission for higher education

Tianjin key medical discipline (specialty) construction project

Publisher

XMLink

Link

https://ejgo.org/pdf/10.3802/jgo.2024.35.e58

Reference32 articles.

1. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative

2. Cancer statistics, 2023

3. Worldwide burden of cancer attributable to HPV by site, country and HPV type

4. Prevention, Screening, Treatment and Follow-Up of Gynecological Cancers: State of Art and Future Perspectives

5. Advances on Prevention and Screening of Gynecologic Tumors: Are We Stepping Forward?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP